Welcome!

News Feed Item

National Cancer Centre Singapore and Clearbridge BioMedics Bring Circulating Tumour Cell Technology Closer To Clinics with "Singapore CTC CoRE"

New collaboration aims to push cancer diagnostics to the next level

SINGAPORE, Jan. 16, 2014 /PRNewswire/ -- A collaboration between National Cancer Centre Singapore (NCCS) and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital (SGH) has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence (CTC CoRE). This new Centre facilitates the use of circulating tumour cells (CTCs)[1] in clinical diagnostics, in order for new technologies to be applied by healthcare institutions.

The CTC CoRE is a key enabler in Singapore's efforts to advance the development of personalised medicine, which is the customised healthcare of an individual patient. The research being undertaken at the CTC CoRE aims to understand the genetic make-up of a patient's cancer cells, which can evolve over time.

To determine the effectiveness of treatment, blood samples will be drawn from the patient pre- and post-treatment. The blood samples are sent to the Cytology Lab at SGH and put through the ClearCell® FX system to separate the cancer cells from other blood components. Using a cytogenetic test, the number of cancer cells are counted and documented. If there is no significant reduction in the number of cancer cells, the oncologist may decide to modify the treatment regime to best combat the cancer. Not only does this result in a dramatic effectiveness in cancer therapy management, it also leads to reduced side effects and significant cost savings.

The CTC CoRE is located at the newly-opened Academia, within SGH's 12,000 sqm Pathology Department. This allows researchers at the CTC CoRE to have access to the cytology, immunohistochemistry, cytogenetics and molecular capabilities at the Department.

The CTC CoRE will focus on a number of research programmes and clinical trials at NCCS and SGH, with support from Clearbridge BioMedics. These include the pilot use of the ClearCell® FX system, which is Clearbridge BioMedics' novel label-free enrichment system for CTCs, first invented at the National University of Singapore. The CTC CoRE will also be developing novel CTC diagnostic assays for personalised medicine that will enable clinicians to tailor therapies to individual patients' unique genetic make-up. It is envisioned that these diagnostic assays will eventually be adopted as part of routine clinical service, enabling clinicians to obtain real-time feedback on therapeutic effectiveness, in order to improve cancer management and patient outcomes.

"With the establishment of this CTC CoRE, Clearbridge BioMedics is now entering the clinical diagnostics field. We are delighted to work with the leading cancer centre in Singapore, to validate the clinical utility of our ClearCell® FX system, which we target to be in the clinic by 2015. The ultimate aim is for the CTC CoRE to allow cancer clinicians to access technologies that reliably process and analyse patients' blood, for actionable clinical results," said Johnson Chen, Director, Clearbridge BioMedics Pte Ltd.

"Circulating tumour cells have the potential to become a powerful tool in how oncologists diagnose, treat and manage cancers. Setting up this CTC CoRE facility will allow our researchers to characterise these cells real-time, even as a patient's tumour evolves due to treatment and time. This will boost NCCS's position as a centre for cancer management, as well as enhance Singapore's reputation as an oncology thought leader in Asia," said Professor Soo Khee Chee, Director, National Cancer Centre Singapore.

"Pathology represents the final bridge between basic science and clinical medicine. The Pathology Department at SGH is able to serve as an incubator for biomedical care, research and innovation. By understanding the genetic make-up of a patient's cancer cells, personalising cancer treatment can be achieved. This collaboration will enable us to leverage on each other's expertise and explore new technologies to improve patient care and outcomes," said Associate Professor Tan Puay Hoon, Head, Department of Pathology, Singapore General Hospital.

[1]

CTCs are cells that have detached from a primary tumour and are circulating in the blood stream. They are rare, with only a few CTCs mixed with billions of blood cells per millitre of blood.

About Clearbridge BioMedics

Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell™ System comprises patent-pending CTChips®, which are microfluidic biochips able to effectively detect, isolate and also retrieve wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive "liquid biopsy" approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

www.clearbridgebiomedics.com

About NCCS

National Cancer Centre Singapore (NCCS) is dedicated to providing a holistic and multidisciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases. Through developing sub-specialisation among its clinical oncologists, NCCS patients receive the best in treatment and care.

The Centre is simultaneously engaged in cutting-edge clinical and translational research which has received international recognition. NCCS was accredited by the Joint Commission International in 2010 for quality patient care and safety.

NCCS, which is set to be a global leading institution, offers specialist training programmes and research training to local and international medical professionals.

www.nccs.com.sg

About SGH

Singapore General Hospital, a member of Singapore Health Services, is the public sector's flagship hospital. Established in 1821, SGH is Singapore's largest acute tertiary hospital with 1,700 beds and national referral centre offering a comprehensive range of 36 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from advanced medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients.

www.sgh.com.sg

SOURCE Clearbridge BioMedics

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...